1/1/2005
Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma
Matthias Augustin et al.

By: Matthias Augustin et al.
Published By: Arzneim.-Forsch./Drug Research

A long-term Iscador treatment in patients with mean- to high-risk primary malignant melanoma appears to be safe. A tumor enhancement was not observed. In comparison with an untreated parallel control group from the same cohort the results of the mistletoe treatment show a significant survival advantage in the UICC-/AJCC stages II-III.
Back to Article List
For more clinical articles and published research on anthroposophic medicine, please visit the AnthroMed Library.
Skip Navigation LinksClinical Studies